Matulane Disease Interactions

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

Switch to professional interaction data

Procarbazine induces myelosuppression, including thrombocytopenia. Bleeding tendencies have included petechiae, purpura, epistaxis, hemoptysis, hematuria, and melena. Therapy with procarbazine should be administered cautiously in patients with bleeding tendencies. Patients should be instructed to immediately report any signs or symptoms of bleeding. Procarbazine should be withheld and/or discontinued if bleeding occurs. Therapy should be withheld if white blood cell counts fall below 4000/mm3 and/or platelet counts fall below 100,000/mm3. Clinical monitoring of hematopoietic function is recommended.

Switch to professional interaction data

Procarbazine induces myelosuppression. Leukopenia, thrombocytopenia, and anemia have been reported during procarbazine therapy. Therapy with procarbazine is contraindicated in patients with inadequate bone marrow reserve as demonstrated by bone marrow aspiration, and should be administered after cautious consideration in patients whose bone marrow reserve may be severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Therapy should be withheld if leukocyte counts fall below 4000/mm3 and/or platelet counts fall below 100,000/mm3. Close monitoring of hematopoietic function is recommended.

Switch to professional interaction data

Procarbazine is metabolized by liver and kidney. Patients with hepatic impairment may be at increased risk for toxicity from procarbazine therapy at recommended dosages. Therapy with procarbazine should be administered cautiously in patients with compromised hepatic function.

Switch to professional interaction data

Procarbazine is metabolized by the liver and kidney. Approximately 70 % of procarbazine is excreted in the urine. Patients with renal impairment may be at increased risk for toxicity from procarbazine therapy at recommended dosages. Therapy with procarbazine should be administered cautiously in patients with compromised renal function.

Switch to professional interaction data